An open-labeled, randomized, single dose, three period, 2-sequence crossover study to investigate the pharmacokinetics of darifenacin when given as 7.5 mg oral doses of a modified release suspension, as compared to the commercial modified release tablet in healthy adult
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2007
At a glance
- Drugs Darifenacin (Primary)
- Indications Overactive bladder
- Focus Pharmacokinetics
- Sponsors Novartis
- 11 Oct 2007 Procter and Gamble reported as trial sponsor.
- 11 Jan 2007 New trial record.